A comparison of different cytotoxicity assays for determination of antitumour effect of chemoterapeutic cis-diamminedichloridoplatinum (II)
Teja Bajt · PeFprints (University of Ljubljana) · 2012
Cancer is becoming a major health problem both in Slovenia and worldwide, as reported in Slovenian National Programme for Cancer Management. According to epidemiological predictions, cancer will soon become the first problem of modern society. Therefore, the progress in treatment development is of crucial importance. Options for cancer treatment include local management, such as surgical oncology and radiation therapy, and systemic management, such as chemotherapy, hormonal therapy and treatment with biotherapeutic agents. Overall progress of medical treatment for various diseases can be seen also in cancer treatment based on chemotherapy. In the last two decades, new advanced knowledge of molecular and cellular biology led to improved therapy. Progress in the understanding of cancer disease coincides with the progress in the evaluation of new anticancer compounds using various screening assays. When developing new screening assays, it is also important to evaluate and compare these assays with the established standard assays to evaluate their efficiency. In our study, we compared the standard clonogenic assay with MTT assay and Presto Blue assay, commonly used for large scale screening of cytotoxic compounds by evaluating cellular cytotoxicity. Our results have demonstrated a good correlation in sensitivity according to the measured IC50 values between clonogenic assay, MTT assay and Presto Blue assay. MTT and Presto Blue assays differ in sensitivity, as sensitivity of Presto Blue assay is higher than sensitivity of MTT assay.